[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mecfs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mecfs":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,142,168,198,219],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100633163","mecfs-brain-fog-cognitive-rehabilitation-trial-100633163",false,"NCT07523113","ME\u002FCFS Brain Fog: Cognitive Rehabilitation Trial","Brain Training for Chronic, Post-viral, Brain Fog: Study A","Inclusion Criteria:\n\n* diagnosis of ME\u002FCFS that preceded cognitive complaints\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* some impairment in the performance of daily activities\n* ≥ 18 years, no upper limit if medically stable\n* reside in the community (as opposed to a hospital or skilled nursing facility)\n* able to travel to the laboratory on multiple occasions\n* has Internet service\n* has a personal computer, laptop, or tablet that can access the Internet\n* sufficiently fit, from both a physical and mental health perspective, to take part in the study\n* adequate sight and hearing to complete the UFOV test\n* adequate thinking skills, e.g., ability to follow directions and retain information to complete UFOV and CTAL, as marked by the judgement of the screener that the candidate is able to adequately complete the UFOV and CTAL\n* sufficient English proficiency (i.e., ability to speak, understand, read, and write to take part in study activities)\n\nExclusion Criteria:\n\n* cognitive impairment due to a developmental disability, psychiatric disorder, or substance abuse, or due to another type of brain injury, such as traumatic brain injury, stroke, or a progressive brain disease, such as Alzheimer's Dementia\n* current substance abuse disorder\n* diagnosis of postural orthostatic tachycardia syndrome (POTS) by a healthcare provider\n* prior cognitive processing speed training on DoubleDecision or a similar program\n* cannot tolerate taVNS\n* prior history of heart attack or other serious cardiac events\n* implanted medical device of any type\n* vasovagal syncope or history of fainting\n* history of seizures or epilepsy\n* temporomandibular Joint (TMJ) syndrome or other conditions that cause substantial jaw pain\n* history of peripheral nerve injury to the head, neck, or face\n* pregnant or breastfeeding\n* not able or willing to get an MRI scan\n* not able or willing to get a blood draw","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to compare two approaches to cognitive rehabilitation in adults with post-viral cognitive syndrome, which resulted in brain fog. All participants will be screened for eligibility prior to participation. Most of the procedures will take place over a phone call or secure telehealth platform (i.e., Zoom). However, participants will be asked to visit UAB on three occasions for blood sample collection and brain imaging (about 2 hours each). Online testing will happen one month before treatment, one day before treatment, one day afterwards, and 6 months afterwards. The study will utilize two different forms of rehabilitation training to improve participants' cognitive ability. Participants will be randomized to one of the two treatment groups. The first treatment approach, known as Constraint-Induced Cognitive Therapy (CICT), will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) online training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation, also known as trans-auricular VNS (taVNS). The second approach, known as Brain Fitness Training (BFT), will include (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, breathing, healthy nutrition, and healthy sleep, (C) education about how relaxation, breathing, nutrition, and sleep are connected to thinking effectiveness, and (D) taVNS. Approximately 30 hours of training will be conducted over a secure telehealth platform (i.e., Zoom) in the span of two- to four- weeks. A typical CICT session will consist of one hour of gaming, with the bulk of the session being spent on cognitive training of the target behaviors and procedures designed to promote transfer of therapeutic gains to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. A typical BFT session will consist of one hour of gaming, training on healthy lifestyle behaviors (i.e., healthy sleep, nutrition, and relaxation habits), as well as procedures designed to promote transfer of behavior changes to daily life. Ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. Training sessions in both conditions will be scheduled based on participants' availability, with the options for sessions scheduled to be as close as every weekday over 2 weeks or as loosely as every other weekday (i.e., over a 4-week span). If a caregiver is available, they will receive training on how to best support participants in their therapeutic program. After the training ends, both groups will receive 4 follow-up phone calls approximately one week apart to promote integration of the gained skills into everyday life. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life.",[26,27,28,29,30,31,32,33],"ME\u002FCFS","ME\u002FCFS Following EBV-associated Infectious Mononucleosis","ME\u002FCFS Following COVID-19","Chronic Fatigue","Chronic Fatigue Syndrome (CFS)","Brain Fog","Cognitive Impairment","Cognitive Dysfunction",[26,29,35,32,33,36,37,38],"Brain fog","post-viral syndrome","Cognitive Rehabilitation","CICT","NOT_YET_RECRUITING","2026-06-04",{"date":42,"type":43},"2026-06-08","ACTUAL",{"date":45,"type":20},"2026-06",{"date":47,"type":20},"2028-06",{"name":49,"class":50},"University of Alabama at Birmingham","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":63,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":110,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":51},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417","NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform",true,"2 Years",{"count":62,"type":20},10000,"10 Years","OBSERVATIONAL","The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[67,26,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109],"Post-Acute COVID-19 Syndrome","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[86,111,112,113,114,115,116,117,118,119,26,120,121,122,123,124,88,125,126,127,128,129,130,31,131],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Mental health","RECRUITING","2026-01-20",{"date":135,"type":43},"2026-01-22",{"date":137,"type":43},"2023-07-05",{"date":139,"type":20},"2030-12-31",{"name":141,"class":50},"Brain Inflammation Collaborative",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":51},"100620025","outreach-medical-care-for-housebound-patients-with-post-covid-19-syndrome-or-mecfs-of-any-cause-access-100620025","NCT07352254","OutreAch MediCal Care for HousEbound Patients With Post-COVID-19 Syndrome or ME\u002FCFS of Any Cause (ACCESS)","OutreAch MediCal Care for HousEbound Patients With Post-COVID-19 Syndrome or ME\u002FCFS of Any Cause","ACCESS","Inclusion Criteria:\n\n* ME\u002FCFS according to the Canadian Consensus Criteria\n* Bell Score ≤ 30\n* Duration of the postexertional malaise (PEM) \\> 14 hours\n* Age \\> 18 years and \\\u003C 70\n\nExclusion Criteria:\n\n\\- Pre-existing conditions or comorbidities that have (or could have) led to a restriction of mobility or mental capacity, such as various diseases of the central nervous system.","69 Years",{"count":152,"type":20},100,[23],"The significance of the Post-COVID Syndrome (PCS) has been widely acknowledged. Various efforts are made to find out about the pathomechanisms behind PCS and to establish therapies. One sub-group of PCS-patients, however, is generally excluded from any studies, and that are those who are unable to visit outpatient clinics or hospitals for diagnostic work up or participation in clinical trials, as they are unable to leave their home and to seek medical support on their own physical and mental capabilities. They are housebound, mostly or totally bedridden. Similar cases are known from myalgic encephalomyelitis\u002Fchronic fatigue syndrome (ME\u002FCFS) of any cause and are graded as moderate to very severe ME\u002FCFS according to the Canadian Consensus criteria. The patients are usually seen by their family doctor and have no access to medical specialists.\n\nThe planned project aims to find out about the prevalence of this most severe manifestation of PCS, the clinical characteristics, the prevalence of mimics, risk factors and impact of the disease on the patients' life and their family\u002Fcaregivers. Individual care and treatment plans will be developed and the effect of monthly consultation hours for patients and caregivers upon the patients' health status and the caregiver burden will be evaluated in a randomized controlled trial. The project will be performed in close cooperation between patients, caregivers, the patient's family doctor and a board of experts from internal medicine, neurology, psychosomatic medicine and general medicine at Hannover Medical School.\n\nWe expect an improvement of the patients' and caregivers wellbeing with intensified medical care. We are aware, however, that intensification of the patient-doctor interaction carries the risk to exacerbate the patients' symptoms. The results of our study will show how current models of care for PCS and ME\u002FCFS patients should be modified to fit to the individual patient's aims and capacities.",[26],[26,157,158],"housebound","house call","2026-01-18",{"date":161,"type":43},"2026-01-21",{"date":163,"type":20},"2026-01",{"date":165,"type":20},"2028-12",{"name":167,"class":50},"Hannover Medical School",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":51},"100544272","phase-2-lift-life-improvement-trial-100544272","NCT06366724","LIFT: Life Improvement Trial","LIFT","Inclusion Criteria:\n\n1. Meet National Academy of Medicine Criteria, Canadian Consensus Criteria (See appendix), and demonstrate orthostatic intolerance for diagnosis of ME\u002FCFS\n2. Participant is ≥ 18 and ≤ 70 years of age at screening, inclusive.\n3. The onset of symptoms prior to December 2023.\n4. Female participant is not pregnant and at least 1 of the following conditions apply:\n\n   1. Not a woman of childbearing potential\n   2. Woman of childbearing potential who agrees to follow the contraceptive guidance. from the time of informed consent.\n5. Participant agrees and can adhere to the study requirements for the length of the study.\n6. Participant has a body mass index (BMI) range of 17 to 40 kg\u002Fm2, inclusive.\n7. Participant agrees not to participate in another interventional study while participating in the present study.\n8. Participant has a functioning smart phone to download and run the DANA Brain Vital Mobile Application.\n\nExclusion Criteria:\n\n1. Pregnant, planning to become pregnant, or breastfeeding.\n2. Any use of opioid medications within 30 days of screening.\n3. Positive urine test for opioids\n4. History of alcohol, opioid or other substance misuse\n5. Participation in another interventional clinical trial in the last 30 days or planned during the trial period.\n6. Allergy to medication components\n7. Participant has any condition which, in the investigator's opinion, makes the participant unsuitable for study participation.\n8. Participant has diabetes mellitus (type 1 or 2).\n9. Participant has undergone an inpatient hospitalization within the 30 days prior to the randomization or has a planned hospitalization or a surgical procedure during the study, which may affect the study assessments, in the opinion of the investigator.\n10. Participant has clinically significant respiratory disease (such as chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, lung infections including tuberculosis, sarcoidosis, thoracic endometriosis, pulmonary fibrosis, and lung cancers) and\u002For cardiac disease (medical history or current clinical findings)\n11. Participant has an active malignancy or any other cancer.\n12. Participant has initiated an exercise regimen within 4 weeks prior to randomization.","70 Years",{"count":177,"type":20},160,[179],"PHASE2","The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus criteria (CCC) for Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS) as well as having specifically Orthostatic Intolerance (OI). Long COVID (LC) subjects will also be included if they meet CCC and have OI.\n\nThis double-blind, placebo-controlled study will involve 160 participants randomized into one of four possible groups: Pyridostigmine\u002FLDN (40), Pyridostigmine\u002FPlacebo (40), LDN\u002FPlacebo (40), Placebo\u002FPlacebo (40). The dose of Pyridostigmine will be carefully titrated from 30mg to 60mg three times a day, and the dose of LDN will be titrated from 1.5 mg to 4.5 mg once daily.\n\nThe trial includes a scale-back plan, allowing participants to reduce their dosage if they experience intolerance symptoms, with adjustments made during weekly visits. This plan provides a personalized approach to medication tolerance, ensuring participant's safety and comfort throughout the trial.\n\nThe time commitment for the participant is approximately three (3) months, and during this time, there will be three (3) in-person visits to BWH and four (4) virtual visits. Study procedures will include two (2) submaximum cardiopulmonary exercise tests, questionnaires (virtually completed), and blood and urine collection. We will be recruiting from the BWH Dyspnea Clinic as well as the Open Medicine Foundation (OMF) StudyME Registry and anticipate the entire trial will take two (2) years to complete.\n\nThe LIFT represents a significant endeavor to improve treatment options for ME\u002FCFS patients and contribute to the broader understanding of this debilitating condition.",[26,86,182],"PASC",[184,185,186,187,188,32,86],"Chronic fatigue","Mestinon","Low Dose Naltrexone","Orthostatic Intolerance","Post exertional malaise","2025-10-21",{"date":191,"type":43},"2025-10-22",{"date":193,"type":43},"2024-09-10",{"date":195,"type":20},"2026-11",{"name":197,"class":50},"Brigham and Women's Hospital",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":204,"maxAge":175,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":51},"100532304","phase-2-the-use-of-directed-probiotics-in-mecfs-myalgic-encephalomyelitischronic-fatigue-syndrome-100532304","NCT06211062","The Use of Directed Probiotics in ME\u002FCFS: Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome","Inclusion Criteria: eligible if all of the following apply:\n\n* Meets IOM ME\u002FCFS case definition criteria,\n* Co-morbid IBS: meets RomeIV criteria for alternating or diarrhea-predominant IBS as reported during screening (technically diagnosed by a physician),\n* Able to provide consent to study,\n* Patients of childbearing potential must practice effective contraception during the study and be willing to continue contraception for at least six months after the intervention,\n* agrees to participate in online surveys and follow-up visits.\n\nExclusion Criteria: ineligible if any of the following apply:\n\n* Probiotics in the past eight weeks,\n* Antibiotics in the past eight weeks,\n* Pregnancy or lactating women,\n* Medical conditions including short bowel syndrome, celiac disease, biliary disease, pancreatitis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), severe cardiovascular, neurological condition, or liver failure,\n* Gastrointestinal surgery within six months of study entry,\n* History of psychiatric disorder, alcohol or illicit drug abuse.","45 Years",{"count":152,"type":20},[179],"This clinical study aims to evaluate the use of i3.1 probiotic in participants who meet the Institute of Medicine (Canadian Consensus Criteria) case definition for ME\u002FCFS and who may or may not be diagnosed with irritable bowel syndrome (IBS). The main questions it aims to answer are:\n\n* how effective is the usage of the i3.1 probiotic to reduce gastrointestinal (GI) inflammation and normalize the GI and systemic\u002Fbrain interface?\n* how well is it working on IBS severity? The study sample is 100 male and female participants aged 45 to 70 years with ME\u002FCFS (per the Canadian Consensus Criteria); one-half of the participants will have co-morbid IBS (per Rome IV criteria). Participants will receive an i3.1 or a placebo and be assessed at baseline, at eight weeks, and at 12 weeks (four weeks post-treatment completion).",[26,209],"IBS - Irritable Bowel Syndrome","2025-03-03",{"date":212,"type":43},"2025-03-04",{"date":214,"type":43},"2022-12-20",{"date":216,"type":20},"2026-02-24",{"name":218,"class":50},"Nova Southeastern University",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":227,"maxAge":4,"enrollmentInfo":228,"targetDuration":230,"studyType":64,"phases":4,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":51},"100499034","multi-center-registry-for-mecfs-100499034","NCT05778006","Multi-Center Registry for ME\u002FCFS","Multi-Center Registry for ME\u002FCFS, Including ME\u002FCFS Following Epstein-Barr Virus-Associated Infectious Mononucleosis (EBV-IM) or Coronavirus Disease 2019 (Covid-19)","MECFS-R","Inclusion Criteria:\n\n* ME\u002FCFS diagnosis (ICD-10 G93.3) based on internationally established criteria\n* Informed consent by patients and\u002For guardian(s)\n\nExclusion Criteria:\n\n* No ME\u002FCFS (ICD-10 G93.3)\n* No informed consent","0 Years",{"count":229,"type":20},650,"30 Years","The ME\u002FCFS study (MECFS-R) aims to create a large-scale registry that provides data on epidemiology, phenotypes, and disease trajectories of and health care for ME\u002FCFS at any age in Germany, which can be used for future clinical trials.",[26,233,27,28],"CFS\u002FME",[26,233,235,236,237,238,239,240,241],"SARS-CoV-2","COVID-10","Post-COVID-19 condition","Chronic fatigue syndrome","Myalgic encephalomyelitis","Epstein-Barr virus","EBV","2025-01-08",{"date":244,"type":43},"2025-01-10",{"date":246,"type":43},"2022-05-31",{"date":248,"type":20},"2052-05-31",{"name":250,"class":50},"Technical University of Munich"]